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ABSTRACT 
THE KINETICS OF DRUG DISSOLUTION IN POLYMERS 





Extrusion has been a most important and widely used continuous process in polymer 
processing for over one hundred and fifty years. However, it has only been recently 
applied and adopted by the pharmaceutical industry to prepare solid oral dosage 
formulations with increased bioavailability for the poorly-water soluble drugs and 
controlled release characteristics for the water-soluble drugs. In pharmaceutical Hot-melt 
extrusion poorly water soluble drug particulates are mixed with water soluble polymer 
excipient particulates and fed in the extruder, where the polymer is melted, after which 
the drug particulates begin to dissolve into the polymer melt. Extrusion-generated mixing 
accelerates dissolution process. One issue concerning the pharmaceutical industry is the 
degradation of drugs when they are exposed to relatively high temperatures of the 
extrusion process (usually 100 ̊C above ambient). In order to keep drugs from thermally 
degrading and at the same time achieving complete dissolution, the dissolution kinetics of 
drugs (APIs) must be specified for any given excipient/API pair, and a variety of 
extrusion conditions. In this work the Brabender Batch Mixer is utilized to determine 
such kinetic data at different concentrations and temperatures by connecting the 
exponential torque decay after the introduction of the API to the API dissolution. The 
time to complete the decay is then associated with the average residence time needed for 
complete dissolution. 
THE KINETICS OF DRUG DISSOLUTION IN POLYMERS 
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Plastics Extrusion has been used in polymer processing for decades; However, it has only 
been recently adopted by the pharmaceutical industry to prepare solid oral dosage 
formulations with increased bioavailability for the poorly-water soluble drugs and 
controlled release characteristics for the water-soluble drugs (Maniruzzaman, Boateng et 
al. 2012). In the case of poorly water-soluble drugs, bioavailability enhancement is 
achieved through amorphization of the crystalline drug, by dissolving it into water-
soluble, hydrophilic polymers, thus forming what is known as a solid solution. Specific 
intermolecular bonds with, and steric hindrance effects by the polymer chain prevent the 
drug from re-crystallizing. Although the extrusion process during the production of solid 
solutions typically takes place below the melting point of the drug, the potential of 
thermal degradation of the API still exist and is in fact a major concern preventing the 
universal applicability of the HME technique as a pharmaceutical manufacturing method.  
To achieve total dissolution of the API in the formulation while minimizing its potential 
thermal degradation, the dissolution kinetics of the API into the excipient must be known. 
In this work, we determine the dissolution kinetics of a model API into a polymeric 






1.2 Background Information 
1.2.1 Hot-melt Extrusion 
Conventional extrusion was first invented for at the end of the eighteenth century (James 
et al., 2004). Since then, it has been used in the plastic, rubber, and food manufacturing 
industry to produce stuffs such as pipes, sheets, and bags. Hot-Melt Extrusion has 
emerged as a novel processing technology in developing molecular dispersions (solid 
solutions) of poorly water-soluble active pharmaceutical ingredients (APIs) into various 
hydrophilic polymer matrices. The Hot-melt extrusion technology has proven to be a 
robust method of producing numerous drug delivery systems and therefore it has been 
found to be useful in pharmaceutical industry as well (Andrews, 2010).(Crowley, 2007). 
HME involves the compaction and conversion of blends from a powder or a granular mix 
into a product of uniform shape (Breitenbach, 2002). During this process, polymer are 
melted and formed into products having different shapes and sizes such as plastic tablets, 
capsules, films, and implants for drug delivery. The extrusion process can be broken 
down to the following general process sections (Chokshi et al., 2004): 
(1) Feeding of the extruder by hopper; 
(2) Mixing, grinding, reducing the particle size, and kneading; 
(3) Flow through the die; 
(4) Extrusion from the die and further downstream processing. 
Processing by HME can improve the bioavailability of the poorly water-soluble active 
pharmaceutical ingredients by dissolving them into water-soluble polymers. At the same 
time, oral dosages with controlled release characteristics can be produced by dispersing 
water-soluble APIs into water-insoluble polymers. The elementary steps of this process 
are identical to the ones involved in conventional plastics melt compounding by extrusion: 
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(1) Feeding particulates; (2) melting; (3) dispersive and distributive mixing; (4) 
devolatilization and stripping; (5) pressurization and pumping. However, for 
pharmaceutical hot-melt extrusion, the API dissolution is an additional and very 
important elementary step, along with melting of the polymeric excipient that precedes it, 
and mixing which accelerates the dissolution process. In the case of solid solutions, the 
drug’s (API) dissolution is an additional and very important elementary step, along with 
melting of the polymeric excipient that precedes it, and mixing which accelerates the 
dissolution process. 
           HME provides several advantages over traditional available pharmaceutical 
processing techniques such as (1) Increased solubility and bioavailability of water-
insoluble compounds; (2) solvent free process; (3) economical process with reduced 
production time, fewer processing steps, and a continuous operation; (4) capabilities of 
sustained, modified, and targeted release; (5) better content uniformity in products; (6) no 
needs for the compressibility of active ingredients; (7) uniform dispersion of fine 
particles; (8) good stability at changing pH  and moisture levels and safe application in 
humans; (9) reduced number of unit operations and production of a wide range of 
performance dosage forms; (10) a range of screw geometries (McGnity et al., 
2004).( Jones et al., 2008).(Grunhagen et al., 1995).(Singhal et al., 2011). However, the 
HME also have disadvantages as well. The main drawbacks of HME include thermal 
process (drug/polymer stability), use of high flow properties of polymers, and excipients 
required and not suitable for relatively high heat sensitive molecules such as microbial 
species and proteins (Grunhagen et al., 1995). (Singhal et al., 2011). 
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           As mentioned above, the thermal degradation of drugs (API) is one of the major 
concern in pharmaceutical HME process. Producing an extrudate that contains a 
molecularly disolved API and at the same time not overexposing the API to high 
processing temperature for long time is one of the major objectives during the extrusion 
of solid solutions. To achieve the balance between complete dissolution of API and 
minimal thermal degradation of the API, the dissolution kinetics of the API particulates 
inside the molten polymeric matrix during extrusion must be known. Melting of the 
polymeric excipient, dispersive/distributive mixing, and API dissolution can occur 
simultaneously during extrusion. Therefore to determine the dissolution kinetics of API, 
the above phenomena must be isolated from each other. One way to achieving this is by 
exploiting the effect of polymer melting, dispersion/ distribution of API particulates and 
API dissolution on the melt viscosity of the polymer matrix: Melt viscosity decreases 
with heat. Addition of particulates in molten polymers increases the melt viscosity. 
Dissolution of an API into molten polymers generally decreases viscosity of virtue of 
plasticization. 
            In this work we determine the dissolution kinetics of Acetaminophen into 
Eudragit EPO by performing batch melt-mixing experiments using a specific addition 
protocol: We first melt-mix the polymer and allow it to reach steady state, then add the 
crystalline API quickly and in small quantities. In this way we minimize the effect of 
dispersion and distribution that occurs prior to and during the dissolution of the API. 
Following the addition of the API to the molten polymer, the dissolution kinetics are then 
determined from the drop in the torque of the processed formulation by virtue of the API 
plasticization of the polymer. 
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1.3 Distributive Mixing and Dispersive Mixing 
Generally, the mixing processes in single or twin screw extruders is induced by laminar 
flow and is generally categorized into two types: dispersive mixing and distributive 
mixing. Dispersive mixing refers to the process involving the particle size reduction of 
particulate cohesive components such as fillers, polymer gels, or liquid droplets. 
Distributive mixing refers to expanding and stretching the interfacial area between the 
components lacking a cohesive force in between and distributing them uniformly 
throughout the volume of the molten polymer. Dispersive mixing is mainly controlled by 
the laminar shear or extensional forces and distributive mixing is mainly controlled only 
by the flow-generated strains and does not require high stresses. According to the 
definitions, the mixing of miscible liquids is regarded as distributive mixing, and mixing 
of hard solid agglomerates, immiscible liquids, and soft agglomerates is regarded as 
dispersive mixing (Tadmor, Gogos, 2006). The dispersive and distributive mixing of 













Figure 1.1  Dispersive mixing and distributive mixing of solid agglomerates and 
immiscible liquid droplets (Tasmor and Gogos, 2006). 
 
Source: Z. Tadmor, C. G. Gogos (2006). Principles of Polymer Processing, John Wily & Sons, Inc. 
Hoboken, NJ, USA. 
 
1.4 Dissolution of API Particles in Polymeric Melt 
The dissolution of API within the polymer largely depends on their physicochemical 
properties. Good blended dispersions require miscibility between the drug and polymer 
(Marsac, 2009). In practice, the majority of drug/polymer systems cannot fully miscibility, 
they may likely to show only partial miscibility. This means that there exists a certain 
thermodynamic solubility of drugs in polymer matrixes. HME can be carried out in two 
distinctly different conditions, referred to here as Case I and Case II:  
           Case I: The processing temperature is above the melting temperature for a semi-     
crystalline polymer, or the softening temperature for an amorphous polymer, (Tg + 50 ~ 
100 ºC) but below the melting point of a drug.  
           Case II: The processing temperature is above both the melting temperature and the 
softening temperature of semi-crystalline or amorphous polymers, respectively, and 
above the melting point of a drug. It is important to be noted that processing temperature 
should be the melt temperature instead of the set temperature of the processing equipment. 
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It should also be noted that the glass transition temperature of an amorphous polymer or 
the melting temperature of a semi-crystalline polymer may decreased if incorporation of 
the API (Crowley et al., 2007). 
 
Figure 1.2 Schematic representation of the morphological changes of the drug and 
polymer system in the solution formation process for Case I.  
 
Source: C.G. Gogos, H. Liu, P. Wang, in: Douroumis, “Hot-Melt Extrusion: Pharmaceutical 
Applications,” Wiley: Chichester, UK, 2012. 
 
           Case I provides a viable method to circumvent the thermal degradation issues. In 
Case I, the drug is processed below its melting point and mixed with a polymer melt, then 
the solid drug particles gradually dissolve into the polymer excipient melt. And this 
process should be able to provide a desirable polymer-drug solid dispersion or solid 
solution. During the HME process, the solid API act as a solute and the polymeric melt 
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act as a solvent. In addition, the dissolution rate and solubility of the API in the polymer 
will increase with higher temperature. 
           The dissolution process of the drug in the polymer melt is schematically shown in 
Figure 1.2. Firstly, the drug particles (black) and polymer particles (white) are fed into 
the batch mixer or an extruder. Then, the polymer particles start melting due to the 
conductive heat from the mixer or extruder barrel and frictional and plastic energy 
dissipation. These two phenomena result in a process charge state that the solid drug 
particles are suspended in a continuous polymer melt matrix. Then the polymer 
molecules start to heat up the API particles and create a mass transfer boundary layer. 
This layer shall be continuously wiped away and replaced with fresh polymer melt 
nearby. The drug molecules diffuse into the polymer melt through the boundary layer, 
and the size of the suspended drug particles will continue to decrease as the diffusion 





Figure 1.3  Schematic representation of the morphological changes of the drug and 
polymer system in the solution formation process for Case II.  
 
Source: C.G. Gogos, H. Liu, P. Wang, in: Douroumis, “Hot-Melt Extrusion: Pharmaceutical 
Applications,” Wiley: Chichester, UK, 2012 
 
           Case II, on the other hand, involves miscible or partially miscible liquid-liquid 
mixing because both the polymer and drug will be melted. As shown in Figure 1.3, the 
drug (black) and polymer (white) particles are fed into an extruder and processed by the 
screw elements. Due to the heat transfer from the extruder barrel or a batch mixer, and 
frictional and plastic dissipation, the polymer particles will melt first. During or after the 
melting of the polymer, the drug particles will melt to droplets and be deformed by the 
mixing flows generated by the screws. The droplets will be deformed along the shear 
direction and blurred the contacting surface between the drug and polymer. As this 
process goes on and with diffusion continuously being carried on, we will finally get a 
homogeneous drug – polymer solution.  
          In both cases discussed above between either the dissolving API particles or the 
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drug droplets and the molten polymer, the diffusion will happened.  The “characteristic 
diffusion time” tD  is proportional to the square of the API phase droplet or ligament 







During the HME process, the relationship between the rate of dissolution of drug 
particles in molten polymer excipients, dm/dt, and the solubility, CS, is described by the 









where m = mass (mol), t = time (s), C = concentration of solute dissolved at a particular 
time (mol∙cm–3), CS = equilibrium solubility (mol∙cm
–3), D = diffusivity (cm2∙s–1) , h = 
apparent thickness (cm) of the aqueous boundary layer (depends on rate of stirring and 
the temperature), and A = surface area available for dissolution (cm2).  
           The equation shows that the drug particle size and size distribution are very 
important to the dissolution rate, since the total contacting surface area of the drug 
particles will be changed accordingly. We can expect a higher dissolution rate if the 
particle size gets smaller. Furthermore, the narrower the drug particle size distribution, 
the more uniform the total dissolution time distribution needed for complete dissolution 




           In order to raise the dissolution rate, the surface area available have to be consider. 
All of we know in extrusion process, the dispersive mixing may break up the drug 
agglomerates or individual particles due to the high shear forces generated by the high 
shear screw elements such as wide kneading blocks or Maddock elements (Tadmor, 
Gogos, 2006). Then, the total contacting surface area of the drug particles to the 
polymeric melt will be increased, thus the dissolution rate will increased. And the 
distributive mixing can homogenize the drug concentration dissolved in the polymeric 
melt, and leading more polymer melt into contact with the suspended drug particles. In 
this way, both effects can raise or maintain the dissolution rate. 
           If the mixer set temperature increases, on the one hand, the diffusion coefficient 
will increase due to the increased temperature and resultant decreased matrix viscosity; 
on the other hand, Cs also will increase. Both of these factors will contribute to an 
increase of the API dissolution rate in the molten polymer excipient. As the screw speed 
increases, the distributive mixing is improved within the chamber as well, and thus a 
higher concentration gradient around the drug particulates is available. Moreover, the 
thickness of the mass transfer boundary layer decreases as the screw speed increases. 










MATERIALS AND METHORDS 
 
2.1 Materials 
Acetaminophen (APAP) (Spectrum Chemicals, Gardena, CA) was used as the model 
crystalline API. APAP is a water-soluble BCS I drug with a Tm of 169–170 
° C. 
Acetaminophen consists of a benzene ring core, substituted by one hydroxyl group and 
the nitrogen atom of an amide group in the para (1, 4) pattern. The amide group is 
acetamide (ethanamide). It is an extensively conjugated system, as the lone pair on the 
hydroxyl oxygen, the benzene pi cloud, the nitrogen lone pair, the p orbital on the 
carbonyl carbon, and the lone pair on the carbonyl oxygen are all conjugated. The 
presence of two activating groups also make the benzene ring highly reactive toward 
electrophilic aromatic substitution. As the substituents are ortho, para-directing and para 
with respect to each other, all positions on the ring are more or less equally activated. The 
conjugation also greatly reduces the basicity of the oxygen and the nitrogen, while 
making the hydroxyl acidic through delocalization of charge developed on the phenoxide 
anion. 
           Eudragit® E is a copolymer composed of neutral methyl and butyl methacrylate, 
and dimethylaminoethyl methacrylate repeating units. It has a Tg ~45˚C. The molar ratio 
of three monomers, methyl methacrylate, butyl methacrylate and dimethylaminoethyl 
methacrylate, is 2:1:1 (Envonik, 2009). Two grades are available which have the same 
chemical structure and molecular weight: one is Eudragit® E PO (E PO) in powder form; 
the other is Eudragit® E 100 in granular form. This copolymer is soluble up to pH=5 and 
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above this pH value is capable of swelling and becoming permeable to water. It is widely 
used for masking unpleasant tastes and odors of drugs, protecting drugs against moisture, 
and as a drug excipient for pharmaceutical applications.  
 
2.2 Methods 
2.2.1 Batch Mixer 
A batch mixer is used to experimentally investigate the effects of extrusion process 
parameters on the drug-polymer mixing. The batch mixer is a heated high-shear laminar 
mixer, which has been extensively used in the plastics and rubber industry to simulate the 
extrusion process or optimize the formulation. The laboratory scale batch mixer used 
requires only 30-60 g of the material and many experiments can be performed in a short 
period, thus making it an attractive choice for the HME study (Ghebre-Sellassie and 
Martin, 2007). Furthermore, the screw speeds can be controlled separately without 
altering the residence time in a batch mixer, which is difficult to realize if an extruder is 
used.  
           All the runs were performed in a Brabender FE-2000 batch intensive mixer 
utilizing counter-rotating screws, as illustrated in Figure 3.1. The batch mixer barrel is 
heated electrically and cooled by air. The melt temperature sensor measures the actual 
processed material temperature during melting and mixing; the torque meter can record 
the resistance of material to the flow created by the counter-rotation of the screws. 
Generally, about 70-75 vol. % fill degree of the chamber is recommended for good 
mixing because the resulting “folding” of the free surfaces is beneficial to distributive 








Figure 2.1  The batch mixer (a) and roller screws (b) (Manufactured by Brabender Corp.) 
 
Source: Liu, H. (May 2010). Hot Melt Mixing/Extrusion and Dissolution of Drug (Indomethacin) in 
Acrylic Copolymer Matrices. Otto H. York Department of Chemical, Biological and Pharmaceutical 




Figure 2.2 The inside of the assembled Brabender batch mixer (without the front plate). 
 
Source: Z. Tadmor, C.G. Gogos, “Principles of Polymer Processing,” Hoboken, NJ, USA, 2nd edition, 
2006.  
 
           The Brabender batch mixer (Shown as Figures 2.1 and 2.2) was used for 
compounding of the materials. All the experiment runs were performed in a Brabender 
FE-2000 batch intensive mixer utilizing Ʃ-co-rotating screws, as illustrated in Figure 2.1. 
During mixing the torque arising from the resistance of material to the flow created by 
the counter-rotation of the screws, is recorded along with the melt temperature. The batch 
mixer barrel is heated with electrical power and cooled down by air. All the materials 
were mixed at 50 rpm for 20 min, while the set temperature of the mixer was 140°C. The 





RESULTS AND DISCUSSION 
 
3.1 Dispersion, Distribution, and Dissolution 
To determine the characteristic constants that describe the dissolution kinetics of an API 
in a molten polymeric excipient, we melt-mixed the API in the polymer matrix at 
different concentrations and temperatures following the addition protocol mentioned in 
Materials and Methods. 
 
Figure 3.1   96%EPO-4%APAP vs. 100%EPO control. 
 
           Figure 3.1 compares the torque traces of pure EPO (control) and the sample 
containing 96%EPO-4%APAP. From the control sample, it can be seen that EPO has 
reached steady state at ~9 min. We can also see that the polymer remains stable for a 
another 11 min, giving us a processing window of 20 min, in which we melt the polymer, 
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allow it to reach steady state, then add the API, dissolve it, and finally allow the binary 
formulation to reach steady state. From the torque tracer of the sample with the drug, we 
can see that the formulation also remains stable for 10 min (after the addition of the API). 
In the sample with 4% API, the torque fluctuation before the point of the maximum 
torque after the addition of APAP, indicates the feeding surge, the wetting of the API 
particles surface and their dispersion and distribution in the molten polymer matrix. The 
final equilibrium torque is associated with the apparent viscosity of the dissolved 
drug/polymer melt mixture in the mixing chamber. 
          The dispersion, distribution and dissolution of an API occur at the same time after 
the addition of the API in the molten polymer. To minimize the effect of dispersion and 
distribution of the API in the polymer matrix, we have kept the addition time and the 
amount of API we are adding in the molten polymer to a minimum. The evolution of the 
torque trace resulting from the addition of the API in the molten polymer can be used to 
approximate the amount of the API dissolved while it is dispersed and distributed in the 
molten polymer matrix. To do this we divide the torque trace into the following parts: 1-2 
is the part beginning with the addition of the drug and ending at the maximum value of 
torque recorded during after the drug is added. 2-3 is from the point where torque is 
maximized until the drug fully dissolves. 3-4 is the steady state torque following the 
dissolution of the drug (respective points on Figure 3.1). The following “cartoon 
representation” of the evolving state of dispersive mixing and dissolution (Figure. 3.2) is 
also used to help depict the phenomena occurring above:  
18 
 
      
Figure 3.2 Cartoon representation of the dispersion, distribution and dissolution of APAP 
in molten Soluplus. 
 
For polymer matrices filled with particulate additives of dimensional aspect ratios near 
unity, that is, nearly spherical, the rheological behavior at low volume fraction 
concentrations φv < 10% resembles the shear thinning nature of the unfilled polymer 
matrix, except that the viscosity is higher and increases with particulate concentration. In 
other words, as expected from suspension theory, the suspended particulates do not 
interact strongly and do not form a particulate network structure. Figure 3.3 plots the 
steady state ratio of the viscosities of suspensions of spherical particles in Newtonian 
liquids, µs, to the viscosity of Newtonian fluid, µf (blue data points). It was constructed 
by Tomas using the data of a number of investigators. A variety of uniform-sized 
particles having diameters of 1-400 µm were used. They included PS and polymethyl 
methacrylate (PMMA) beads, rubber latex, and glass spheres. To avoid settling, either the 
density of the suspending medium was adjusted or a medium of high viscosity was used. 
The maximum packing density was determined by extrapolating a plot of 1/[(µs/µf)-1] vs. 




Table 3.1 Suspension/fluid and Standard Error (SE) 
APAP % 
Suspension/fluid SE 
3 1.14 0.028359 
4 1.16 0.009616 
5 1.20 0.051369 
10 1.52 0.048851 
 
           In Figure 3.3 we also plot the torque ratio (which is proportional to the viscosity of 
the molten materials) of point 2 over point 1 (red data points, values in Table 3.1) for 
different drug concentrations and compare these with the viscosity ratios of suspensions 
from Tomas. It can be seen that for both data sets, the viscosity ratios for similar volume 
fractions of added/suspended particles are very close. This is a strong indication that, 
only a small portion of the added API has dissolved during the dispersion and distribution 
of the API particles in the molten polymer matrix (between point 1 and 2). If a substantial 
portion had dissolved, then the viscosity ratios for the API particles would be 
significantly lower compared to these for non-dissolving particles, due to the 
plasticization effect of the dissolved API on the polymer. Therefore we can safely assume 
that the part of the curve corresponding to the dissolution of the API (points 2 to 3) is due 






Figure 3.3   Comparison of viscosity ratios of suspensions (Thomas et al) and viscosity 
ratios of suspended drug particles in molten polymer matrix (this work).   
 
3.2 Dissolution 
3.2.1 Drugs Concentration Effect 
Figure 3.5 shows the torque traces corresponding to the dissolution process of the API 
into the molten polymer (points 2-4 in Figure 3.1) of formulations containing different 
amount of APAP. Since the dissolution of a crystalline API is a physical reaction, it can 
be described by rate laws governing chemical reactions. The differential rate law 
describes how the rate of reaction varies with the concentration of various species, drugs 
in this case, in the system. The rate of drugs dissolved is proportional to the rate of 
change in concentrations of the drug, meaning, the rate is proportional to a derivative of a 
concentration. The rate of the change either increases or decreases as time passes. In 
exponential decay, the rate of change decreases over time - the rate of the decay becomes 






















graph, these functions are not straight lines. Generally, there are three reaction orders, 
such as zero order, first order, and second order. As Table 3.2 showing below: 
 









Slope of Kinetic 
Plot 
Zero  - d[A]/dt = k [A]=[A]0 - kt [A] vs. t  - k 
First  - d[A]/dt = k[A] [A]=[A]0 exp(-kt) ln[A] vs. t  - k 
Second  - d[A]/dt = k[A]^2 [A]=[A]0/(1+kt[A]0) 1/[A] vs. t  - k 
 
          In this work, we consider the rate in torque drop to be proportional to the rate of 
dissolution of the API in the molten polymer, by virtue of the plasticization effect of the 
API. We can, therefore, plot [A] vs. t, ln[A] vs. t, and 1/[A] vs. t to determine the reaction 







Figure 3.4   The relationship of [A] vs.t, ln[A] vs.t, and 1/[A] vs.t. 
 
           Figure 3.4, shows the torque of 4% APAP plotted as [A], ln[A], and 1/[A] with 
time t. From the trend lines corresponding the above plots, we see that the best 
approximation to a straight line is obtained from a first order reaction (R2= 0.7054), 
where R2 is “The Plotting Fitted Values”: a statistical measure of how close the data are 
to the fitted regression line. 
 
Table 3.3  The Function of Dissolution Curve in Each Order. 
Zero Order y = 58.35 × t –  53.873,   R2 =  0.0313 
First Order y = − 0.8797 × t –  0.7465,   R2 =  0.7054 
Second Order y = − 0.1047 × t +  0.3827,   R2 =  0.4992 
 
y = -0.1047x + 0.3827
R² = 0.4992
y = -0.8797x - 0.7465
R² = 0.7054




























Because 0.7054 > 0.4992 > 0.0313, we consider the dissolution of APAP to be 
characterized by first order reaction kinetics. That is: 
 𝐲 = 𝐍𝐞(−𝐤𝐭) (3.0) 
   
 
Figure 3.5   Torque decrease of the melt processed formulation during the dissolution of 
various amount of APAP. 
 
           Figure 3.5 shows the torque decrease of the melt-processed formulation due to the 
dissolution of different concentrations of APAP, curve fitted with the exponential decay 
model, while Table 3.4 shows the calculated parameters of the exponential decay model 
for the different concentrations of APAP. The torque drop evolution due to the 
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dissolution and the resulting plasticization effect of the dissolved APAP on the melt 
viscosity of Soluplus is consistent with the amount of drug added to the molten polymer: 
For the highest concentration of API added (10%) the initial toque at which the 
dissolution of the API begins, is highest compared to the lower concentrations due to the 
higher volume fraction of suspended solid particles in the melt, as discussed above. 
Additionally, the drop in torque for the highest concentration of drug is also the highest, 
since it involves the largest fraction of the dissolving drug, which acts as a plasticizer for 
the polymer melt.     
 
Table 3.4  Exponential Decay Model Parameters 
 
 
           The physical meaning of the parameters of the exponential decay function are as 
follows: (N) is the scaling factor of the decay function and corresponds to the value of the 
y-axis (torque/viscosity) at t=0 (before any dissolution takes place). In our case (N) 
corresponds to the highest value of torque, which is proportional to the amount of the 
added API, following the addition, dispersion and distribution of the API in the polymer 
melt, and the initiation of the API dissolution (point 2 in Figure 3.1). Plotting the value of 
(N) vs. the initial concentration of APAP in the formulation yields a straight line, the 
slope of which denotes the proportionality between the amounts of API added and the 
Concentration 3% 4% 5% 10% 
N[Pre-exponential 
Number] 1.01 1.48 1.79 3.41 
k 2.01 3.31 2.83 2.53 
R2 
0.93 0.98 0.97 0.97 
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corresponding increase in the torque of the melt. (k) in the exponential decay function 
indicates the decay rate of the material’s torque or viscosity due, in this case, to the 
dissolution rate of the API. We consider this to be a constant with an average value of 
2.46 ± 0.24, the relative standard error being within acceptable range (< 10%).         
  
Figure 3.6  The relationship between N and Initial APAP Concentration.  
 
Table 3.5  [k] Value Results at Different Concentrations of added particulate APAP with 
Standard Deviation and Standard Error Values 
 
Concentration 3 5 10 AV SD SE 
k 2.01 2.83 2.53 2.46 0.41 0.24 
 
The result obtained indicate that k is not a function of the initial concentration of the 
added APAP. 
 
3.2.2   Dissolution of the API at Different Processing Temperatures   
To determine the relationship between dissolution of the API and processing temperature, 
as well as the activation energy for dissolution, we carried out experiments at a fixed API 
concentration (4%) at three different temperatures, namely, 130˚, 140˚ and 150˚C. We 




















chose these three temperatures, because they are within the “HME Processing Window” 
for the APAP/EPO system. Figure 3.7 shows the torque drop of the molten formulation 
after the addition of 4% APAP at these three different temperatures.  
 







Table 3.6  Model Parameters in Different Temperature  
Temperature(ºC) 130 140 150 
N[Pre-exponential 
Number]  2.81 1.48 0.87 
k 3.99 3.31 4.31 
R2 
0.99 0.98 0.99 
 
Table 3.6 lists the parameters determined from curve fitting of the exponential decay 
model to the experimental data obtained at different temperatures. 
 
 
Figure 3.8  The relationship between N and Temperature.  
 
 
According to the Arrhenius Equation, describing an “Arrhenius rate process” the k value 
can be represented as follows: 


























The ln[k] is a function of [ 
1
T







 which R 
refers gas constant and Ea can be defined as the minimum energy required to start a 
reaction (Generally, Ea = f(T)). Table 3.7 lists the each ln[k] values corresponding to 







) can be regard as a constant value 
cause its Standard Error value is small enough (generally, less than 10% of Average 
value). So the activation energy for APIs dissolution process in excipients is insensitive 
for temperature [T] as present in Figure3.9.  
 








0.00248 0.00242 0.00236    




558.199 494.968 618.549 557.2 61.8 35.7 
 
The value and units of the Gas Constant R is: 8.3145[J/mol.ºK]. Therefore, the Activation 
Energy for Dissolution as measured by the viscosity decrease of the dissolving APAP in 
EPO system is Ea = (557.2)(8.3145) = 4.6 [kJ/mol] and does not vary with temperature in 









           Using these two parameters N and k evaluated through the torque time decay 
results in the Brabender internal mixer, the exponential decay function can depict the 
kinetics of drug’s dissolution in the APAP/EPO system in the API concentration range of 
3 – 10% and in the Processing Temperature range of 130 - 150ºC. It was found that in 
these ranges, neither the drag concentration, nor the processing temperature affect k. On 
the other hand N (that is, the torque or system viscosity) is affected by both processing 
temperature and added APAP particulates concentration. The first dependence is 
Arrhenius in nature, and the second obeys the solid suspension viscosity-concentration 
behavior. Combining Figure 3.6 and Figure 3.8, the N behavior can be depicted by the 
function of concentration and temperature, shown in Equation 3.2 and Equation 3.3 
below 
N =  0.3346 × [𝐶]  +  0.0813,   R2  =  0.9971    (3.2) 
N =  −0.0972 × [𝑇]  +  15.32,   R2  =  0.9561 (3.3) 
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           Thus, keeping temperature constant and different concentration of drugs we can 
use function Equation (3.4) to get its dissolution kinetics; conversely, for the same drug 
concentration but different process temperature, Equation (3.5) can be used to determine 
the time dependent dissolution y = Ne(−kt), where the y value equals N when t = 0 and 
when t = ∞ then N or y = 0. 
 y =  N[0.3346 × C +  0.0813] × exp(−k × t)    (3.4) 
y =  N[−0.0972 × T +  15.324] × exp(−k × t) (3.5) 
The time required for the torque to reach a value equal to (N/𝐞𝟓) = 0.0067N (0.0165N) 
can be considered safely to be the time needed for complete dissolution of the APAP in 
EPO under given conditions in the experimental ranges used. And this time should be 














SUMMARY AND CONCLUSIONS 
 
4.1 Summary 
The NJIT/PPI research group studying pharmaceutical Hot Melt Extrusion, within which 
the author of this thesis worked, considers this process to be a special case of reactive 
polymer compounding, in which the particulate additive compounded dissolves during 
compounding. In other words, the dissolution process represents the “reaction”, not a 
chemical one but a physical one. In this work, we examined experimentally the process of 
an API dissolving in polymer excipient with a focus of minimizing the effects of 
dispersive and distributive mixing after the addition of the API particulates into the 
molten EPO during batch mixing/processing in a Brabender mixer. In this way we were 
able to follow the exponential decay in the Brabender torque and determine the 
dissolution kinetics of the API, since it is the only physical process taking place after the 
addition of the API. The torque reduction is entirely attributable to the dissolution of the 
API, which acts as a plasticizer, reducing the polymer excipient viscosity. 
Acetaminophen (APAP) and Eudragit® E PO (EPO) were chosen as the model API and 
polymer. The experimental times required for the complete reduction of the torque under 
different processing conditions are taken as the minimum required residence times during 
Hot Melt Extrusion.  
           The analysis of the entirety of the experimental work conducted with APAP 
dissolving in EPO under different process temperatures and at different APAP 
concentrations, resulted in the specification of the two dissolution rates expressions, 
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namely, Equation 3.3. and Equation 3.4. The dissolution of APIs in polymer excipients is 
an exponential decay and characterized by two different decay function parameters, N 
and k.  
           With the two rate expressions (Equations 3.3. and 3.4) and specific values of the 
parameters for the APAP/EPO API/polymer excipient pair is possible for oral dosage 
engineers and scientists to specify the Hot Melt Extrusion (HME) minimum residence 
times, which will guarantee the complete dissolution of the API and at the same time 
minimize the API degradation during HME. All this eliminates the need of conducting 
costly and time-consuming HME experiments. Therefore, the work conducted in this 
thesis represents a powerful methodology of specifying the HME process “operating 
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